Medy-Tox Inc.

As of March 31, 2026, Medy-Tox Inc. carries a market capitalization of 660.23B, placing it among publicly traded companies globally. Its enterprise value stands at 748.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medy-Tox Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of March 31, 2026, Medy-Tox Inc. has 6.52M shares outstanding.

As of March 31, 2026, Medy-Tox Inc. trades at a trailing price-to-earnings ratio of 32.68. The price-to-sales ratio is 2.76, and the price-to-book ratio stands at 1.76.

As of March 31, 2026, Medy-Tox Inc. trades at an EV/EBITDA multiple of 39.58 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 39.58 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 748.06B versus a market cap of 660.23B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Medy-Tox Inc. maintains a current ratio of 1.01, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Medy-Tox Inc. posted a return on equity (ROE) of 4.92, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 3.52, measuring how efficiently the asset base is converted into earnings. The company generates approximately 319.19M in revenue per employee across its workforce of 764.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.86 indicates how many times Medy-Tox Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Medy-Tox Inc. recorded an income tax benefit of -8.46B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 11.74B, leaving 20.59B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Medy-Tox Inc.'s stock has declined approximately 44.07% over the past 52 weeks. The 50-day moving average sits at 69,164.00, while the 200-day moving average is 94,088.50.

Over the twelve months ended March 31, 2026, Medy-Tox Inc. generated 244.02B in revenue and converted that into 20.59B in net income, yielding earnings per share of 3,041.12. EBITDA reached 18.90B, while operating income came in at 18.90B.

As of March 31, 2026, Medy-Tox Inc. holds 42.53B in cash and equivalents against 125.33B in total debt, resulting in a net debt position of 80.64B. Total book value stands at 374.67B, with working capital of 1.46B providing operational flexibility.

Medy-Tox Inc. produced 68.92B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -32.32B in capital expenditures, free cash flow totaled 36.61B - equivalent to 5,512.44 per share.

Over the twelve months ended March 31, 2026, Medy-Tox Inc. posted a gross margin of 60.23, reflecting its pricing power and cost economics. The operating margin of 7.75 and net profit margin of 8.44 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 5.44, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 8.40, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Medy-Tox Inc. shareholders.

Medy-Tox Inc.'s most recent stock split took place on December 28, 2022 with a 20:21 split ratio.

As of March 31, 2026, Medy-Tox Inc. has an Altman Z-Score of 3.82, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.